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Inhaled long-acting &-agonists are frequently used for the treatment of asthma. When introduced to the 
market, the drug was accompanied by a debate among physicians and scientists raising warnings against 
the use of /?,iagonists, leading to a risk of tachyphylaxis and worsening of asthma control. During recent 
years, much of these warnings have been counter proved and there has been a tendency to institute 
treatment with long-acting &agonists somewhat earlier in the course than before’. However, the exact 
place for long-acting &agonists in the asthma treatment plans, still needs to be established. 
While /$-agonists have been shown to have anti-inflammatory activity in vitro and after single allergen 
exposure, this effect seems to disappear with regular treatment. The same phenomena have been shown 
to protect against obstruction caused by metacholine inhalation or exercise. Although the protective 
effect diminishes or even disappears, no signs of rebound phenomena or increased susceptibility to 
provocative stimulus has been shown. Thus, in contrast to earlier reports after regular use of short-acting 
&agonists, no signs of tachyphylaxis have been reported after use of long-acting &agonists. Moreover, 
the bronchodilatatory effect seems to be fairly stable after regular treatment, even though some reports 
claims that this effect diminishes over time. 
The present article is a review of some data involved in this debate. The authors conclude that 
long-acting &-agonists are a valuable contribution to the asthma treatment repertoire. However, the 
drugs should be regarded as long-acting bronchodilatators, supplementing the use of inhaled cortico- 
steroids. The rapid appearing tolerance towards allergen-induced and provoked bronchial obstruction 
prevents these drugs from being used as monotherapy; they should be used only in combination with’ 
sufficient anti-inflammatory treatment, i.e. inhaled corticosteroids. 
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Introduction 
A long-acting oral &-agonist (bambuterol) has been 
on the market in a number of European countries for 
several years without creating a lot of interest. In 
contrast, the two inhaled long-acting &-agonists 
recently introduced (salmeterol and formoterol) have 
been the source of considerable dispute concerning 
their place in therapy. Salmeterol and formoterol 
appeared on the European market 5-6 yr ago. Con- 
comitantly, there has been intense debate on the 
potential risk of regular &stimulation (1,2). Despite 
differing opinions in this matter, no other dose 
interval than twice daily has been recommended for 
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inhaled long-acting B,-agoqists until the recent ap- 
proval of formoterol in Sweden, where once-daily use, 
i.e. in the evening if the indication is night asthma, or 
in the morning if the main indication is daytime 
symptoms, is recommended. Unfortunately, there are 
no data comparing these two dosing strategies. 
Long-acting p,-agonists and Asthma 
Symptoms 
It is generally accepted that treatment with long- 
acting &agonists should be started when the asthma 
is not controlled with a moderate dose of inhaled 
corticosteroids. The recommended dose when consid- 
ering addition of this treatment varies between differ- 
ent asthma management guidelines. In Sweden, it has 
been proposed that long-acting &agonists could be 
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evaluated when a daily dose of 800 ,ug of beclometha- 
sane dipropionate (BDP) or budesonide (BUD) is 
insufficient to control the disease. The current British 
guidelines, on the other hand, are more conservative 
and recommend later introduction of inhaled long- 
acting &agonists. 
In patients suffering from night asthma, the intro- 
duction of inhaled long-acting j&-agonist has been 
shown to reduce symptoms rapidly and to improve 
quality of life (3,4). The corresponding data regarding 
daytime symptoms are not as impressive. There are a 
few published studies comparing the effect of a com- 
bination of long-acting &agonists and low-dose 
corticosteroids with the effect of a higher dose of 
inhaled steroids. Greening et al. compared salmeterol 
50 ,ug b.i.d. and BDP 200 pug b.i.d. with BDP 500 pg 
b.i.d. over a treatment period of 6 months. Mean 
morning peak flow rate (PEFR) increase significantly 
in the combined arm (average 20-25 1 min - ‘). More- 
over, there was a significant reduction in both night- 
time and daytime symptoms. The effect from adding 
salmeterol appeared early in the course, with the 
largest difference between the groups occurring 
within the first weeks. However, improvement also 
occurred in the high-dose steroid group, but with a 
slower onset. After 6 months of treatment, the differ- 
ences in symptom reduction between the groups was 
no longer significant, neither at night nor during the 
day (5). It should be noted that the study was a 
multicentre study with data collected from 99 differ- 
ent general practitioners. A significant drop out was 
seen in both arms (38%) and the results should be 
interpreted with care. 
In another study, Woolcock et al. came to the same 
conclusion comparing BDP 500 lug b.i.d. + salmeterol 
50-1OOyg b.i.d. with BDP 1OOO~g b.i.d. (6). In this 
more symptomatic group of asthmatics, the difference 
in symptom reduction between those treated with 
salmeterol and those not was significant for the 
6-month study period. 
It may be concluded that good symptomatic con- 
trol is achieved by adding long-acting P,-agonists to 
inhaled steroids. The effect appears rapidly while the 
positive effect from an increased dose of the inhaled 
steroid has a slower onset of action. The positive 
effect on lung function is very predictable as revers- 
ibility after treatment with a &agonist is an inclusion 
criterion in almost all clinical trials in asthma patients. 
Long-acting P,-agonists and Airway 
Inflammation : 
Although it is clearly recommended in guidelines that 
long-acting &agonists should only be used in com- 
bination with inhaled corticosteroids, it is the 
authors’ experience that some doctors are using them 
as ‘monotherapy’. The rationale behind this is prob- 
ably the belief that long-acting &agonists not only 
act as a symptom reliever, but also have anti- 
inflammatory properties. Comparing salmeterol to 
BDP as controller therapy, however, showed obvious 
advantages for the inhaled steroid (7). 
A lot of convincing in vitro data has shown that 
long-acting @,-agonists (as well as short-acting) do 
have a mast cell stabilizing activity, but may also 
affect other cell types, such as eosinophils, neu- 
trophils, lymphocytes and macrophages [for review, 
see (S)]. However, these studies mainly refer to short 
time exposure in vitro, and although some studies 
have tried to find such effects in vivo (9), there are no 
data available indicating any clinically relevant anti- 
inflammatory activity whatsoever from &agonists 
in vivo. If such an effect does exist, it is probably only 
present during the first few days of treatment. 
The authors strongly support the recommendations 
in guidelines that inhaled long-acting /&-agonists 
should only be used in combination with sufficient 
doses of inhaled steroids. 
Long-acting jJ,-agonists and Protection 
Against Provocative Stimuli 
Pedersen et al. have shown that a single dose of 
salmeterol 5Opg (in contrast to short-acting 
&-agonists) protects from both the early- and the 
late-phase reaction after allergen provocation (10). 
Moreover, after pre-treatment with placebo, an 
increase of eosinophils and eosinophilic cationic pro- 
tein (ECP) was seen. This increase was prevented 
by pre-treatment with salmeterol, 50 or 100 pg. The 
authors interpreted the results as a possible anti- 
inflammatory effect, comparable to the effect seen 
after regular steroid treatment. However, recent data 
indicate that the protective effect by long-acting 
j&-agonists on allergen-induced bronchoconstriction 
rapidly disappear with regular treatment (11). That 
regular treatment with short-acting &agonists leads 
to decreased protection against allergen-induced 
bronchoconstriction has been shown previously by 
Cockroft et al. (12). They treated mild allergic asth- 
matics with salbutamol 400,~~ug q.i.d. regularly for 2 
weeks. During this time, increased responsiveness to 
allergen was observed. 
As with allergen provocation, loss of protective 
effect has been observed with exercise-induced bron- 
choconstriction and with metacholine challenge. 
Ramage et al. showed that pre-treatment with sal- 
meter01 50 pug caused significant protection against 
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exercise-induced bronchoconstriction 6 and 12 h after 
the first dose (13). This protective effect was lost after 
4 weeks of regular treatment with salmeterol 50,~~g 
b.i.d. Cheung et al. showed that pre-treatment with 
salmeterol 50yg caused an increase of almost 3.5 
doubling doses in metacholine (PD,,) after the first 
dose (14). After 4 and 8 weeks of regular treatment, 
an increase of one doubling dose in PD,, remained. 
The results of these studies indicate that tolerance 
may develop to the bronchoprotective effects of sal- 
meterol. This happens early in the course, being 
maximal after 7 days of regular treatment (15). How- 
ever, it needs to be stated that even though the 
protective effect clearly diminishes and even dis- 
appears, there are no reports of increased sensitivity 
(rebound phenomena) during or after treatment with 
inhaled long-acting &-agonists. Such rebound effects 
have been observed with short-acting j&-agonists 
(16,17). Whether this indicates a real biological dif- 
ference or is a result of differences in study design is 
an open question. 
/3,-receptor Sub-sensitivity: Facts or 
Fiction? 
Several authors have shown that long-term treatment 
of mild to moderate asthmatics with salmeterol 50 pg 
b.i.d. cause persistent bronchodilatation measured as 
increase of morning PEFR. This prolonged bron- 
chodilatation seems to contradict development of 
P-receptor subsensitivity. As this dose of salmeterol 
does not provide maximal bronchodilatation, it is not 
obvious that this is the clinically relevant question. 
More important is whether or not regular treatment 
with long-acting &agonist per se interferes with the 
ability of maximal response to high doses of (short- 
acting) &agonist. This question has been addressed 
by several authors. Grove et al. (18) showed that 
regular treatment of 17 asthmatic patients with sal- 
meter01 50,~~g b.i.d. for 4 weeks caused significant 
reduction of P,-receptor density on blood lym- 
phocytes, compared to placebo. Moreover, the bron- 
chodilator response to salbutamol was diminished in 
the regularly treated group. The same phenomenon 
was later shown by Newnham et al. (19) by using 
formoterol24pg b.i.d. for 4 weeks. Both these studies 
are somewhat difficult to interpret regarding the 
bronchodilator response, as the problem with shift in 
baseline is not properly addressed. Fuglesang et al. 
have recently reported a study in children where they 
compared the maximal bronchodilator response to 
terbutaline after regular treatment for three weeks 
with either BUD 100 pug b.i.d., salmeterol 5Opg b.i.d. 
or placebo (20). They found a significantly reduced 
bronchodilator response after regular treatment with 
salmeterol compared with BUD or placebo. This was 
also significant when baseline was considered. 
From these data, it may be argued that whether or 
not a true subsensitivity to bronchodilator effect 
really exists is still an open question, The clinical 
importance is even more questionable. 
Systemic Corticosteroids Counteract the 
Tolerance Inducing Effect 
Systemic glucocorticoids have been shown to upregu- 
late the &receptor affinity in vitro (21,22). Regarding 
long-acting P,-agonists and inhaled steroids, the com- 
bination was not found to prevent the development of 
tolerance measured as loss of bronchoprotective 
effect (23). Recently it has been shown that a single 
dose of systemic prednisolone (50 mg) rapidly 
reverses the P-receptor subsensitivity induced by regu- 
lar treatment with formoterol (24) This effect does 
not seem to be achievable with inhaled fluticasone 
proprionate in doses up to 2OOOpg b.i.d. (25). This 
indicates that the phenomenon of P-receptor sub- 
sensitivity is not restricted to the airways, indeed 
adding a new perspective to how one should regard 
asthma. 
Salmeterol DS Formoterol 
There are some differences in potential clinical im- 
portance between salmeterol and formoterol. Firstly, 
formoterol has a rapid onset of action, comparable to 
that of short-acting drugs such as salbutamol and 
terbutaline (26); and secondly, salmeterol is a partial 
agonist, while formoterol is a drug with more full 
agonist properties (27). 
The more rapid onset of action of formoterol is a 
potential advantage in some patients. With b.i.d. 
dosing, a substantial number of patients combine the 
morning dose of salmeterol with a short-acting 
&agonist. The need for such a combination could be 
expected to be less frequent with a more rapid onset 
of action. The short onset of action also gives the 
drug a potential use as an occasional symptom 
reliever on a p.r.n. basis. Such use should, however, 
be studied from a safety aspect before it can be 
generally recommended. Salmeterol does not seem to 
have any potential for such use. The difference in 
onset of action is less important if the drug is used 
once or twice daily in stable asthmatics without 
current symptoms. 
The differences between salmeterol and formoterol 
regarding full vs partial agonism are based on in vitro 
comparisons. The maximal relaxant effect (efficacy) 
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on a contracted muscle is higher for a drug with full 
agonism than for a partial agonist. In a situation 
when the bronchial tone is high and the receptors are 
saturated with a partial agonist, the drug may theor- 
etically act as a P-blocker inhibiting the effect of other 
P-agonists. The Dundee group have reported a dimin- 
ished acute effect of &agonists after chronic treat- 
ment with either drug (18,19). As mentioned 
previously, these results are controversial, but if the 
observation is valid, there are two different possible 
explanations. The loss of effect might be due either to 
development of tolerance -which is theoretically 
more plausible, the fuller agonist the compound 
is-or to the partial agonism with subsequent 
P-blocking properties. Neither of these properties 
has yet, however, been demonstrated to be of any 
importance in clinical use. 
Both drugs have been shown to be effective for at 
least 12 h after administration, and as a longer dur- 
ation of action, in the authors’ opinion, would not be 
clinically useful, any differences after this time are 
unimportant. 
Conclusions 
Long-acting /&-agonists are safe and efficient bron- 
chodilators, and their introduction on the market has 
caused significant relief for a large number of 
patients. Long-acting &agonists should be intro- 
duced as ‘symptomatic treatment’ i.e. to achieve a 
long-standing bronchodilatation when this is not 
reached by inhaled corticosteroids, alone or com- 
bined with a short-acting /&-agonist. 
Today, there are no data indicating that regular 
long-acting &agonist use has any anti-inflammatory 
action. In contrast, it has been shown that tolerance 
appears rapidly towards allergen-, exercise- or 
metacholine-induced bronchoconstriction. Thus, the 
rationale behind a twice-daily dosing schedule could 
be questioned. Until further data are available, the 
authors recommend that long-acting P,-agonists 
should be used at night, to protect against night 
asthma symptoms. Daytime use is more questionable 
as short-acting drugs could be expected to be as 
effective in reducing these symptoms when taken 
repeatedly. A number of studies indicate, however, 
that this is not the case, and patients with symptoms 
in spite of an adequate dose of inhaled steroids also 
seem to benefit from inhaled long-acting P-agonists in 
the day time. Thus, it is important to rule out the 
possibility of sub-optimal steroid dose - in most 
instances, there is no other way to do this than to 
try a course of intensive steroid treatment-before 
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